Literature DB >> 7334071

Impaired antibody responses to a pneumococcal polysaccharide vaccine in patients with non-Hodgkin's lymphoma in remission.

O F Ballester, M Shurafa, H Toben, K S Kumar, C L Burek.   

Abstract

Eight patients with non-Hodgkin's lymphoma who have been in complete clinical remission for the mean of 23.3 months were evaluated for their antibody responses to a pneumococcal vaccine. The results were correlated with lymphocyte subpopulations, serum immunoglobulin levels, and in vitro mitogenic responses to phytohemagglutinin, concanavalin and pokeweed mitogen. Two patients with normal antibody responses had immunoglobulin levels and mitogenesis within the range of controls. Impaired antibody responses in the remaining six patients were correlated either with marked depressed mitogenesis to phytohemagglutinin or with low levels of IgA. Impaired humoral immune responses seem to persist in these patients even after several months of sustained clinical remission.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334071     DOI: 10.1007/bf00915384

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  12 in total

1.  Editorial: Measurement of delayed skin-test responses.

Authors:  J E Sokal
Journal:  N Engl J Med       Date:  1975-09-04       Impact factor: 91.245

2.  Antibody response in hematologic patients.

Authors:  S SASLAW; H N CARLISLE; B BOURONCLE
Journal:  Proc Soc Exp Biol Med       Date:  1961-03

3.  Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease.

Authors:  G R Siber; S A Weitzman; A C Aisenberg; H J Weinstein; G Schiffman
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

4.  Infections in patients with malignant lymphoma treated with combination chemotherapy.

Authors:  R Feld; G P Bodey
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

Review 5.  Immunodeficiency and the pathogenesis of lymphoma and leukemia.

Authors:  S Louie; R S Schwartz
Journal:  Semin Hematol       Date:  1978-04       Impact factor: 3.851

6.  A microplate method of enzyme-linked immunosorbent assay and its application to malaria.

Authors:  A Voller; D Bidwell; G Huldt; E Engvall
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

7.  Effects of radiochemotherapy and splenectomy on cellular immunity in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  R Steele; T Han
Journal:  Cancer       Date:  1978-07       Impact factor: 6.860

8.  Immunodeficiency in patients with non-Hodgkin lymphomas.

Authors:  S E Jones; K Griffith; P Dombrowski; J A Gaines
Journal:  Blood       Date:  1977-03       Impact factor: 22.113

9.  T lymphocytes bearing complement receptors in a patient with chronic lymphocytic leukaemia.

Authors:  H R Toben; R G Smith
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

10.  Neoantigen response in patients successfully treated for lymphoma. A Southwest Oncology Group study.

Authors:  G W King; P C Grozea; H J Eyre; A F LoBuglio
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

View more
  3 in total

1.  Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines.

Authors:  S Petrasch; O Kühnemund; A Reinacher; M Uppenkamp; R Reinert; W Schmiegel; R Lütticken; G Brittinger
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

2.  Prospective study on humoral immune response induced by fungal infection in patients with hematologic malignancies.

Authors:  I Kostiala; E Elonen; P Ylipaavalniemi; A A Kostiala
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

3.  Follow-up of antibodies against single-stranded DNA in patients with haematological malignancies.

Authors:  A A Kostiala; M Gripenberg; E Elonen; G Gripenberg; I Kostiala
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.